Similar articles for PMID: 17709711

Year	Number of Results
1995	1
1996	2
1997	1
1998	1
1999	3
2000	7
2001	8
2002	2
2003	18
2004	23
2005	35
2006	38
2007	56
2008	30
2009	36
2010	28
2011	20
2012	25
2013	22
2014	17
2015	11
2016	21
2017	25
2018	18
2019	13
2020	5
2021	3
2023	1
2024	0

1

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.

Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG. Rose JW, et al. Neurology. 2007 Aug 21;69(8):785-9. doi: 10.1212/01.wnl.0000267662.41734.1f. Neurology. 2007. PMID: 17709711 Clinical Trial.

2

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.

Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW; CHOICE investigators. Wynn D, et al. Lancet Neurol. 2010 Apr;9(4):381-90. doi: 10.1016/S1474-4422(10)70033-8. Epub 2010 Feb 15. Lancet Neurol. 2010. PMID: 20163990 Clinical Trial.

3

Management of worsening multiple sclerosis with mitoxantrone: a review.

Fox EJ. Fox EJ. Clin Ther. 2006 Apr;28(4):461-74. doi: 10.1016/j.clinthera.2006.04.013. Clin Ther. 2006. PMID: 16750460 Review.

4

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T; Laquinimod in Relapsing MS Study Group. Polman C, et al. Neurology. 2005 Mar 22;64(6):987-91. doi: 10.1212/01.WNL.0000154520.48391.69. Neurology. 2005. PMID: 15781813 Clinical Trial.

5

High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.

Barbero P, Verdun E, Bergui M, Pipieri A, Clerico M, Cucci A, Ricci A, Bergamasco B, Durelli L. Barbero P, et al. J Neurol Sci. 2004 Jul 15;222(1-2):13-9. doi: 10.1016/j.jns.2004.03.023. J Neurol Sci. 2004. PMID: 15240190 Clinical Trial.

6

A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN.

Patti F, Amato MP, Filippi M, Gallo P, Trojano M, Comi GC. Patti F, et al. J Neurol Sci. 2004 Aug 15;223(1):69-71. doi: 10.1016/j.jns.2004.04.023. J Neurol Sci. 2004. PMID: 15261564 Clinical Trial.

7

Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.

Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi M; 9006 Study Group. Cohen JA, et al. Neurology. 2007 Mar 20;68(12):939-44. doi: 10.1212/01.wnl.0000257109.61671.06. Neurology. 2007. PMID: 17372130 Clinical Trial.

8

Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.

Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V. Lanzillo R, et al. Mult Scler. 2010 Apr;16(4):450-4. doi: 10.1177/1352458509358909. Epub 2010 Feb 11. Mult Scler. 2010. PMID: 20150398 Clinical Trial.

9

Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.

Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL 3rd, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF, Perryman JE, Scott TF, Skaramagas TT, Zhang H; ACT Investigators. Cohen JA, et al. Mult Scler. 2008 Apr;14(3):370-82. doi: 10.1177/1352458507083189. Epub 2008 Jan 21. Mult Scler. 2008. PMID: 18208877 Clinical Trial.

10

Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.

Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL 3rd, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M; ACT Investigators. Cohen JA, et al. Neurology. 2009 Feb 10;72(6):535-41. doi: 10.1212/01.wnl.0000341934.12142.74. Neurology. 2009. PMID: 19204263 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

421 results

Results by year